Recent studies have demonstrated that sCLUcould regulate ERK1/2 activity in renal cell cancer [20], pancreatic cancer [15], monocytes/macrophages [21] and lung cancer [22]. This evidence concerns the gene MAPK3 and renal cell adenocarcinoma.